TAK-071-2002: A Randomized, Double-Blind, Placebo-Controlled, 2 Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients with Cognitive Impairment